Steven Pieper - Jul 28, 2021 Form 3 Insider Report for XERIS PHARMACEUTICALS INC (XERS)

Role
Senior Vice President, General Counsel and Corporate Secretary Exhibit 24.1: Power of Attorney attached
Signature
/s/ Beth Hecht
Stock symbol
XERS
Transactions as of
Jul 28, 2021
Transactions value $
$0
Form type
3
Date filed
7/29/2021, 06:04 PM
Next filing
Oct 5, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding XERS Common Stock 58.9K Jul 28, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding XERS Stock Option (Right to Buy) Jul 28, 2021 Common Shares 16.8K $1.55 Direct F1, F2
holding XERS Stock Option (Right to Buy) Jul 28, 2021 Common Shares 2.64K $1.55 Direct F1, F2
holding XERS Stock Option (Right to Buy) Jul 28, 2021 Common Shares 14K $5.93 Direct F1, F2
holding XERS Stock Option (Right to Buy) Jul 28, 2021 Common Shares 6.53K $6.37 Direct F1
holding XERS Stock Option (Right to Buy) Jul 28, 2021 Common Shares 5.97K $6.37 Direct F1
holding XERS Stock Option (Right to Buy) Jul 28, 2021 Common Shares 27.9K $4.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months
F2 These options are early exercisable.

Remarks:

Senior Vice President, General Counsel and Corporate Secretary Exhibit 24.1: Power of Attorney attached